↓ Skip to main content

Genetic polymorphisms of autophagy‐related gene 5 (ATG5) rs473543 predict different disease‐free survivals of triple‐negative breast cancer patients receiving anthracycline‐ and/or taxane‐based…

Overview of attention for article published in Cancer Communications, January 2018
Altmetric Badge

Mentioned by

twitter
4 X users

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Genetic polymorphisms of autophagy‐related gene 5 (ATG5) rs473543 predict different disease‐free survivals of triple‐negative breast cancer patients receiving anthracycline‐ and/or taxane‐based adjuvant chemotherapy
Published in
Cancer Communications, January 2018
DOI 10.1186/s40880-018-0268-1
Pubmed ID
Authors

Meiying Li, Fei Ma, Jiayu Wang, Qing Li, Pin Zhang, Peng Yuan, Yang Luo, Ruigang Cai, Ying Fan, Shanshan Chen, Qiao Li, Binghe Xu

Abstract

Autophagy plays a crucial role in chemotherapy resistance of triple-negative breast cancer (TNBC). Hence, autophagy-related gene 5 (ATG5), an essential molecule involved in autophagy regulation, is presumably associated with recurrence of TNBC. This study was aimed to investigate the potential influence of single-nucleotide polymorphisms in ATG5 on the disease-free survival (DFS) of early-stage TNBC patients treated with anthracycline- and/or taxane-based chemotherapy. We genotyped ATG5 SNP rs473543 in a cohort of 316 TNBC patients treated with anthracycline- and/or taxane-based chemotherapy using the sequenom's MassARRAY system. Kaplan-Meier survival analysis and Cox proportional hazard regression analysis were used to analyze the association between ATG5 rs473543 genotypes and the clinical outcome of TNBC patients. Three genotypes, AA, GA, and GG, were detected in the rs473543 of ATG5 gene. The distribution of ATG5 rs473543 genotypes was significantly different between patients with and without recurrence (P = 0.024). Kaplan-Meier survival analysis showed that patients carrying A allele of ATG5 rs473543 had an increased risk of recurrence and shorter DFS compared with those carrying the variant genotype GG in rs473543 (P = 0.034). In addition, after adjusting for clinical factors, multivariate Cox regression analyses revealed that the AA/GA genotype of rs473543 was an independent predictor for DFS (hazard risk [HR], 1.73; 95% confidence interval [CI], 1.04-2.87; P = 0.034). In addition, DFS was shorter in node-negative patients with the presence of A allele (AA/GA) than in those with the absence of A allele (P = 0.027). ATG5 rs473543 genotypes may serve as a potential marker for predicting recurrence of early-stage TNBC patients who received anthracycline-and/or taxane-based regimens as adjuvant chemotherapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 20%
Student > Master 2 13%
Student > Doctoral Student 1 7%
Professor 1 7%
Student > Bachelor 1 7%
Other 2 13%
Unknown 5 33%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 4 27%
Pharmacology, Toxicology and Pharmaceutical Science 2 13%
Medicine and Dentistry 2 13%
Agricultural and Biological Sciences 1 7%
Unknown 6 40%